The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas
Abstract Background Prolactinoma is a functional pituitary adenoma that secretes excessive prolactin. Dopamine agonists (DAs) such as bromocriptine (BRC) are the first-line treatment for prolactinomas, but the resistance rate is increasing year by year, creating a clinical challenge. Therefore, it i...
Guardado en:
Autores principales: | Shuman Wang, Aihua Wang, Yu Zhang, Kejing Zhu, Xiong Wang, Yonggang Chen, Jinhu Wu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/153f41d5a590442696c639e7294f4b90 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis
por: Yunzhi Zou, et al.
Publicado: (2021) -
Resultados visuales en pacientes con macroprolactinoma tratados con agonistas de dopamina
por: Cuevas,José Luis, et al.
Publicado: (2013) -
Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
por: Via MA
Publicado: (2010) -
Sustained compensatory p38 MAPK signaling following treatment with MAPK inhibitors induces the immunosuppressive protein CD73 in cancer: combined targeting could improve outcomes
por: Mikkel G. Terp, et al.
Publicado: (2021) -
Dopamine, a co-regulatory component, bridges the central nervous system and the immune system
por: Mingan Li, et al.
Publicado: (2022)